Predictors of in-hospital mortality in diabetic patients with non-ST-elevation myocardial infarction

Seyyed Mojtaba Ghorashi1, Mojtaba Salarifar2, Hamidreza Poorhosseini2, Saeed Sadeghian1, Arash Jalali1, Hassan Aghajani2, Ali-Mohammad Haji-Zeinali2 and Negar Omidi1*

Abstract

Background: There have been little data about the additive effects of coronary risk factors on mortality in diabetic patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI). This study aimed to evaluate the predictors of mortality in diabetic patients presenting with NSTEMI. All patients admitted to Tehran Heart Center (THC) with a confirmed diagnosis of NSTEMI and a history of diabetes mellitus (DM) type 2 between September 2003 and April 2017 were included. Clinical characteristics and paraclinical data such as lipid profiles, creatinine, hemoglobin, and hemoglobin A1C (HbA1C) were evaluated in these patients to predict in-hospital mortality. The approach for model calibration was a logistic regression with the backward elimination method.

Results: Of a total of 9158 patients with non-ST-segment elevation myocardial infarction, 3133 had diabetes mellitus type 2 and met our criteria to enter the final analysis. In the multivariable analysis, age, chronic obstructive pulmonary disease, and a severely reduced left ventricular ejection fraction (LVEF) significantly increased the rate of in-hospital mortality, whereas mildly and moderately reduced left ventricular ejection fraction did not increase the rate of mortality.

Conclusions: Age, chronic obstructive pulmonary disease (COPD), and severely reduced LVEF (< 30%) independently increased in-hospital mortality in our diabetic patients with a confirmed diagnosis of NSTEMI. Severely reduced LVEF had the strongest relationship with in-hospital mortality, whereas the mean HbA1C level and the type of DM management exerted no significant effect on in-hospital mortality.

Keywords: Myocardial infarction, Mortality, Diabetes mellitus, Ejection fraction

Background

The most frequent cause of mortality and morbidity is cardiovascular disease (CVD), [1] and the greatest burden of diseases worldwide belongs to ischemic heart disease [2]. Coronary artery disease (CAD) is a common condition that affects several million adults. Despite a reduction in the CVD rate in developed countries, ischemic heart disease is still high in developing countries. Acute myocardial infarction (MI) encompasses ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Although in-hospital mortality is higher in STEMI than NSTEMI, the chance of 30 days and 1-year mortality is higher in NSTEMI compared to STEMI [3]. The global prevalence of diabetes mellitus (DM) in 2019 is estimated to be 9.3%, rising to 10.2% by 2030 and 10.9% (700 million) by 2045 [4]. DM is an established risk factor for CAD [5]. Moreover, diabetic patients with MI have adverse cardiovascular effects and higher in-hospital morbidity and mortality rates [6]. Previous studies
have focused on mortality in patients with NSTEMI and indicated that DM is one of the major risk factors [7]. Nonetheless, the additive effects of risk factors in diabetic patients with MI have yet to be fully elucidated, and so do the factors influencing the mortality of MI in diabetic patients. Accordingly, in the present study, we sought to determine these specific factors in diabetic patients presenting with NSTEMI, which, to the best of our knowledge, has not been assessed so far.

Methods
Data source
This study was performed on patients admitted to Tehran Heart Center (THC) with a confirmed diagnosis of NSTEMI between September 2003 and April 2017 using the THC Acute Coronary Syndrome Registry. The final analysis was conducted only on patients with a history of type 2 DM.

Study population
Of a total of 9158 patients, 3133 patients were qualified to enter our study. For the purposes of predicting inhospital mortality, information was gathered on baseline characteristics (age and sex), major coronary risk factors (hypertension, dyslipidemia, cigarette smoking, opium abuse, and family history), past medical history (previous MI, coronary artery bypass graft, and chronic obstructive pulmonary disease (COPD)) type of DM treatment (diet, oral medication, and insulin or combination therapy), laboratory tests (HbA1C), high-density lipoprotein, low-density lipoprotein, total cholesterol, triglyceride, creatinine, and hemoglobin), LVEF on admission, and drug history (aspirin, clopidogrel, statins, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)).

Ethical statement
The study protocol was approved by the Ethics Committee of Tehran University of Medical Sciences, and it conforms to the ethical guidelines of the 2013 Declaration of Helsinki.

Definitions and study endpoints
NSTEMI was defined as non-persistent ST-segment elevation in patients with acute chest pain and myocardocyte necrosis (the detection of an increase and/or decrease in a cardiac biomarker) [8]. DM was defined as either a fasting blood glucose level of more than 126 mg/dL or a history of prescribed medications [9]. Hypertension was defined as blood pressure more than 140/90 mm Hg or the use of antihypertensive medications [10]. Dyslipidemia was defined as a minimum total cholesterol level of 240 mg/dL, a minimum triglyceride level of 200 mg/dL, a high-density lipoprotein level of less than 40 mg/dL in men and less than 50 mg/dL in women, a minimum low-density lipoprotein level of 160 mg/dL, or a history of prescribed lipid-lowering medications [11]. The body mass index was defined as a weight-to-height ratio, calculated by dividing weight (kg) by the square of height (m); and a minimum index of 30 kg/m² was defined as obesity [12]. Cigarette smoking and opium consumption status was defined as a current user or a daily user, a former user who had quit at least three months previously, and a never user based on their self-report [13]. COPD was defined as a chronic condition with abnormal pulmonary function (post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity < 0.70 and FEV1 < 80% with frequent exacerbation, necessitating recurrent hospitalization and the long-term use of bronchodilators) [14]. The LVEF (determined by echocardiography) was categorized as normal (50–70%), mildly reduced (40–49%), moderately reduced (30–39%), and severely reduced (< 30%) [15]. Chronic kidney disease (CKD) or renal failure was defined based on glomerular filtration rate (GFR< 60 ml/min per 1.73 m²) for ≥ 3 months [16].

Statistical analysis
The univariate effects of the variables on mortality were evaluated applying a logistic regression model, and the effects were reported through odds ratios (OR) with 95% confidence intervals (CIs). Variables with a P value of less than 0.05 in the univariate analyses were candidates to enter the final model. A logistic regression model with the backward elimination method (with 0.05 and 0.1 as entry and removal probabilities) was used to detect the multiple predictors of mortality. A complete-case analysis was conducted. The discrimination power of the final model was assessed using the area under the receiver operating characteristic curve. Model calibration was evaluated using the Hosmer–Lemeshow goodness of fit test. All the statistical analyses were conducted with IBM SPSS Statistics for Windows, version 23.0 (Armonk, NY: IBM Corp).

Results
Population
In total, of 9158 patients with a confirmed diagnosis of NSTEMI between September 2003 and April 2017 in THC, 3133 patients had type 2 DM and were enrolled in the final analysis. The baseline characteristics of the patients according to their discharge conditions are demonstrated in Table 1. The study population (mean age of 64.7 ± 10.59 years) was comprised of mostly men (57%). The most frequent conventional risk factor was cigarette smoking (75.8%). The most common DM management
strategy was an only oral antihyperglycemic agent (59.9%), followed by only insulin (20.9%). Finally, 117 (3.7%) patients died within the hospital admission period that 47% of them were women (55/117).

### Univariate analysis

Age, renal failure, and severely reduced LVEF showed statistically significant differences between the surviving and non-surviving patients (Table 1). Dyslipidemia,

---

**Table 1** Baseline characteristics of the study population and univariable effects on mortality

| Characteristic      | Total      | Alive      | Dead       | OR  | 95% CI | P value |
|---------------------|------------|------------|------------|-----|--------|---------|
|                     |            | Lower      | Upper      |     |        |         |
| Age (y), mean (SD)  | 64.7 (10.59)| 64.5 (10.53)| 69.8 (10.9) | 1.05| 1.03   | 1.07    | 0.001   |
| Sex (male), n (%)   | 1787 (57.0)| 1725 (57.2)| 62 (53.0)  | 0.84| 0.58   | 1.22    | 0.368   |
| Hypertension, n (%) | 2200 (70.2)| 2130 (70.6)| 70 (59.8)  | 0.62| 0.42   | 0.90    | 0.013   |
| Dyslipidemia, n (%) | 2020 (64.5)| 1954 (64.9)| 66 (56.4)  | 0.70| 0.48   | 1.01    | 0.062   |
| Family history, n (%) | 261 (8.5) | 255 (8.6) | 6 (5.5)   | 0.61| 0.26   | 1.40    | 0.247   |
| COPD, n (%)         | 44 (1.4)   | 40 (1.3)   | 4 (3.4)    | 2.63| 0.92   | 7.48    | 0.070   |
| CABG, n (%)         | 553 (17.7) | 532 (17.7) | 21 (17.9)  | 1.02| 0.63   | 1.65    | 0.934   |
| Previous MI, n (%)  | 524 (17.0) | 504 (16.9) | 20 (17.2)  | 1.02| 0.62   | 1.66    | 0.933   |
| RF, n (%)           | 317 (10.1) | 289 (9.6)  | 28 (23.9)  | 2.96| 1.90   | 4.61    | <0.001  |
| LVEF, n (%)         |            |            |            |     |        |         |
| Normal              | 470 (18.4) | 463 (18.8) | 7 (7.4)    |     | <0.001 |         |
| Mild reduction      | 459 (18.0) | 540 (18.3) | 9 (9.6)    | 1.32| 0.48   | 3.58    | 0.582   |
| Moderate reduction  | 1044 (40.8)| 1013 (41.1)| 31 (33.0)  | 2.02| 0.88   | 4.63    | 0.095   |
| Severe reduction    | 583 (22.8) | 536 (21.8) | 47 (50.0)  | 5.80| 2.59   | 12.95   | <0.001  |
| ACEI/ARB, n (%)     | 1356 (45.7)| 1313 (46.0)| 43 (37.7)  | 0.71| 0.48   | 1.04    | 0.084   |
| Aspirin, n (%)      | 2239 (59.8)| 2197 (95.9)| 42 (39.3)  | 0.60| 0.18   | 1.98    | 0.408   |
| Clopidogrel, n (%)  | 1108 (85.6)| 1087 (85.8)| 21 (77.8)  | 0.58| 0.23   | 1.45    | 0.246   |
| Statin, n (%)       | 1920 (88.0)| 1886 (88)  | 34 (82.9)  | 0.65| 0.28   | 1.50    | 0.322   |
| Body mass index (kg/m²), n (%) | 27.9 (4.65) | 27.9 (4.63) | 28.3 (5.97) | 1.01| 0.95   | 1.08    | 0.615   |
| Cigarette smoking, n (%) |            |            |            |     |        |         |
| Current             | 2350 (75.8)| 2255 (75.6)| 95 (981.2) |     | 0.320  |         |
| Former              | 294 (75.8) | 287 (9.6)  | 7 (6.0)    | 0.57| 0.26   | 1.26    | 0.168   |
| Never               | 453 (14.7) | 440 (14.8) | 15 912.8  | 0.80| 0.46   | 1.40    | 0.454   |
| Opium, n (%)        |            |            |            |     |        |         |
| Current             | 2897 (92.5)| 2784 (92.4)| 113 (96.6) |     | 0.403  |         |
| Former              | 33 (1.1)   | 33 (1.1)   | 0 (0.0)    |     | 0.998  |         |
| Never               | 201 (6.4)  | 197 (6.5)  | 4 (3.4)    | 0.50| 0.18   | 1.37    | 0.178   |
| Diabetes treatment, n (%) |            |            |            |     |        |         |
| Diet                | 174 (5.6)  | 169 (5.7)  | 5 (4.6)    | 0.55| 0.19   | 1.59    | 0.275   |
| Oral                | 1854 (59.9)| 1805 (60.5)| 49 (45.4)  | 0.51| 0.27   | 0.95    | 0.036   |
| Insulin             | 674 (20.9) | 613 (20.5) | 34 (31.5)  | 1.04| 0.54   | 2.01    | 0.895   |
| Combination         | 160 (5.2)  | 153 (5.1)  | 79 (6.5)   | 0.86| 0.33   | 2.20    | 0.757   |
| Total cholesterol, median | 165 (134, 198) | 165 (134, 198) | 160.5 (133, 204) | 0.9 | 0.99 | 1.00 | 0.717 |
| Triglyceride, median | 149 (106, 213) | 149 (106, 213) | 137.5 (94, 183) | 0.99 | 0.99 | 1.00 | 0.267 |
| HDL, median         | 38.5 (10.57)| 38.5 (10.58)| 36.8 (10.14)| 0.98| 0.95 | 1.01 | 0.321 |
| LDL, median         | 99 (74, 126)| 99 (74, 126)| 99 (70, 127)| 1.00| 0.99 | 1.00 | 0.943 |
| Creatinine (mg/dL), median | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.2) | 1.1 (0.8, 1.6) | 1.20| 0.99 | 1.45 | 0.051 |
| HbA1C, n (%)        | 8.2 (7.1, 9.5)| 8.8 (7.2, 10.1)| 1.135 | 0.94| 1.36 | 0.18 | 0.178 |
| Hemoglobin (mg/dL), n (%) | 13.8 (2.03) | 13.8 (2.03) | 13.2 (2.01) | 0.86| 0.73 | 1.02 | 0.098 |

Continuous variables are presented as the mean (SD) or the median (25th and 75th percentiles)

Categorical variables are described as frequencies (percentages); n (%)

COPD chronic obstructive pulmonary disease, CABG coronary artery bypass graft, MI myocardial infarction, RF renal failure, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, HDL high-density lipoprotein, LDL low-density lipoprotein
cigarette smoking, and opium consumption had no significant effect on in-hospital mortality. Neither drug history of antiplatelet and statin nor a previous history of coronary artery bypass graft surgery and MI significantly differed between surviving and non-surviving patients.

**Multivariate analysis**

In the multivariable analysis with the backward elimination method, among all the variables, age, COPD, LVEF, and ACEI/ARBs consumption were identified as the independent predictors of in-hospital mortality (Table 2). The strongest predictor was severely reduced LVEF (<30%) (OR: 6.137, 95% CI: 1.335–28.221; \( P = 0.020 \)). Although COPD had a higher OR (OR: 8.33, 95% CI: 1.59–43.58; \( P = 0.012 \)) with respect to the prevalence in our population, its power decreased. The Forest plot (Fig. 1) displays the independent impact of each predictor. As is illustrated in the plot, the use of ACEIs or AT2R blockers was protective against mortality.

**Discussion**

Patients with DM are more susceptible to acute coronary syndrome and have higher risks for in-hospital mortality and major adverse cardiovascular events than are patients without DM [6, 17]. In this study, we aimed to evaluate the predictors associated with in-hospital mortality in type 2 diabetic patients with confirmed NSTEMI.

According to our univariable analysis, diabetic patients who were managed by only oral antihyperglycemic agents had a better outcome compared with ones treated by only insulin or combination therapy. Based on previous studies, it appears that non-insulin-treated DM is associated with better DM control and better outcomes than insulin-treated ones. Non-insulin medications used in the DM treatment reduced the incidence of cardiovascular events in diabetic patients and have a beneficial effect on MI in follow-up [18]. In a study by Noman et al. [19] on early mortality following percutaneous coronary intervention (PCI) in diabetic patients, higher mortality occurred in insulin-treated patients.

CKD is an independent predictor of cardiovascular morbidity and mortality [20]. We have seen that renal failure is associated with higher in-hospital mortality only in the univariable study. In addition, the higher creatinine level had a trend to a worse outcome. Wang et al. [21], in a study regarding the impact of CKD on clinical outcomes in NSTEMI receiving PCI, found that in-hospital mortality does not significantly differ between patients with and without advanced CKD. However, long-term follow-up of CKD patients consistently reveals poor outcomes. Therefore, the presence of CKD should

---

**Table 2** Multivariable analysis of the risk factors predicting mortality

| Variable                  | OR   | 95% CI          | \( P \) value |
|---------------------------|------|-----------------|---------------|
| Age                       | 1.046| 1.001–1.092     | 0.046         |
| COPD                      | 8.329| 1.592–43.580    | 0.012         |
| LVEF                      |      |                 |               |
| Mildly reduced            | 1.153| 0.186–7.127     | 0.879         |
| Moderately reduced        | 1.306| 0.258–6.596     | 0.747         |
| Severely reduced          | 6.137| 1.335–28.221    | 0.020         |
| ACEI or ARB               | 0.335| 0.128–0.877     | 0.026         |

\( \text{COPD} \text{ chronic obstructive pulmonary disease, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker} \)
be taken into consideration in the management of MI and warrants further research.

Another independent risk factor for in-hospital mortality was COPD. The COPD prevalence among study participants was very low (1.4%), and the COPD prevalence in patients who died was 3.4% (4/117). Zhang et al. [22] evaluated patients who underwent PCI and concluded that a history of COPD had a strong association with adverse cardiac events and increased risk of all-cause mortality, which attributed to initial lower baseline LVEF and higher prevalence of coronary risk factors. Agarwal et al. [23], in a study regarding the impact of COPD on patients with STEMI, found an increased risk of in-hospital mortality among these patients and in their STEMI patients with a history of DM. Moreover, they conveyed the point that a positive correlation between COPD and in-hospital mortality is due to the increased risk of new-onset heart failure, acute respiratory failure, and cardiogenic shock in those patients. Another study by Enríquez et al. [24] demonstrated that in patients presenting with NSTEMI, a history of chronic lung disease was independently associated with a higher risk of in-hospital mortality. Two reasons would be enumerated for this association, including an elevated risk of bleeding and more variable approaches to care of NSTEMI because of the individual physician and system decisions that cause lower and delayed revascularization in NSTEMI patients. Still, further research is needed to investigate the predictive power of COPD for mortality in each subtype of MI.

Our results revealed no statistically significant difference between gender and mortality. In line with our findings, Wang et al. [25] conducted an exhaustive meta-analysis evaluating the possible role of gender in the mortality rate in the short and long term after NSTEMI. They observed no significant differences between men and women in the prognosis of NSTEMI. Further research is recommended on the impact of sex on mortality in diabetic patients with NSTEMI.

Age increased in-hospital mortality in our diabetic patients with NSTEMI as an independent factor. According to McNamara et al. [26] study using ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry–GWTG (Get With the Guidelines) data-base, increasing age was associated with in-hospital mortality.

Even though the mean HbA1C level was above the normal level in our study, it had no statistically significant relationship with in-hospital mortality. Liang et al. [27] studied patients with MI in China and revealed that HbA1C had no significant effect on mortality.

Our study showed that severely reduced LVEF is a robust predictor of in-hospital mortality. This finding has two implications. Firstly, mortality does not increase significantly until the LVEF drops to less than 30%, and secondly, a mildly or moderately reduced LVEF has no significant correlation with in-hospital mortality. Chehab et al. [28] demonstrated that patients with acute MI and reduced EF (<35%) developed higher in-hospital mortality. According to Emet et al.’s [29] studies in Istanbul, there was a significant association between mean LVEF and in-hospital mortality.

As indicated in our study, the univariate analysis demonstrated that hypertension had a protective effect against in-hospital mortality although this effect was not observed in multivariable analysis. It gives the impression that using ACEIs/ARBs was the major cause of protective effects, not hypertension. History of ACEIs/ARBs usage conferred a protective effect against in-hospital mortality among diabetic patients with NSTEMI. Zuanetti et al. [30] conducted a study on diabetic patients with suspected Acute MI and showed that early treatment with ACEIs caused a reduction in 6-week mortality. Niskanen et al. [31] studied patients with hypertension and showed that ACEIs diminished mortality and cardiovascular events in those with DM. According to previous studies, this finding might be because of the efficacy of ACEIs in ameliorating the enlargement of the ventricles and preventing decrements in ventricular function [32].

We used paper or electronic documented data and databases and, as a result, encountered some missing values. We had no mid-term and long-term follow-ups of our patients is another weakness of note. We recommend that future investigations evaluate long-term outcomes in relation to risk factors and their prognosis.

Conclusions
Age and severely reduced systolic function constituted the independent predictive factors of mortality in our diabetic patients presenting with NSTEMI. Severely reduced LVEF (<30%) had the strongest relationship with in-hospital mortality, whereas the mean HbA1C level and the type of treatment (either oral hypoglycemic agents or insulin) exerted no significant effect on in-hospital mortality. Furthermore, ACEIs/ARBs in drug history conferred protective effects in our diabetic patients with NSTEMI.

Abbreviations
ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; CAD: Coronary artery disease; CI: Confidence interval; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; CVD: Cardiovascular disease; DM: Diabetes mellitus; FEV1: Forced expiratory volume in 1s; GFR: Glomerular filtration rate; HbA1C: Hemoglobin A1C; LVEF: Left ventricular ejection fraction; NSTEMI: Non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; THC: Tehran Heart Center.
Acknowledgements
The authors thank the staff of THC.

Authors’ contributions
SS and MS contributed to the study conception and design. Material preparation, data collection, and analysis were performed by AJ, NO, HP, SMG, AH, HA, and MS. The first draft of the manuscript was written by NO, SMG and all the authors commented on the previous versions of the manuscript. All the authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets analyzed during the current study are not publicly available due to the institutional policy but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The methods applied in this study followed the Helsinki declaration. The design and conduct of the study were approved by the Ethics Committee of Tehran University of Medical Sciences. The informed written consent to participate in the study was provided by all participants.

Consent for publication
Informed written consent was obtained from all the study participants.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Cardiovascular Disease Research, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Interventional Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Received: 20 September 2021 Accepted: 15 March 2022
Published online: 28 March 2022

References
1. Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005–2013. 2014.
2. Moran AE, Tzong KY, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M et al (2014) Variations in ischemic heart disease burden by age, country, and income: the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart 9(1):91–99
3. Awad HH, Tisminetzky M, Metry D, McManus D, Yarzebski J, Gore JM et al (2016) Magnitude, treatment, and impact of diabetes mellitus in patients hospitalized with non-ST-segment elevation myocardial infarction: a community-based study. Diab Vasc Dis Res 13(1):13–20
4. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al (2019) Global and regional diabetes prevalence estimates for 2019 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 157:107843
5. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241(19):2035–2038
6. Zhou M, Liu J, Hoo Y, Liu J, Huo Y, Smith SC et al (2018) Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovasc Diabetol 17(1):147
7. Bataille V, Ferrieres J, Danchin N, Prymira E, Zeller M, Simon T et al (2019) Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: data from the FAST-MI 2005 registry. Eur Heart J Acute Cardiovasc Care 8(3):218–230
8. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315
9. Alberti KGMM, Zimmet PF (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 15(7):539–53
10. Weber MA, Schiffin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al (2014) Clinical practice guidelines for the management of hypertension in the community. J Clin Hypertens 16(1):14–26
11. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB et al (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 44(3):720–732
12. Niedzielna J, Huzdik B, Niedzielna N, Gajos M, Gierlotka M, Wasilewski J et al (2014) The obesity paradox in acute coronary syndrome: a meta-analysis. Springer, Berlin
13. Balter LJ, Good KP, Barrett SP (2015) Smoking cue reactivity in current smokers, former smokers and never smokers. Addict Behav 45:26–29
14. Iheanacho I, Zhang S, King D, Rizzo M, Imsaas AL (2020) Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis 15:439–460
15. Kosaraju A, Makaryus AN (2018) Left ventricular ejection fraction. StatPearls, Treasure
16. Levey AS, Coresh J, Bolton K, Cuffehton B, Harvey KS, Ikizler TA, et al/K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl. 1).
17. Yong J, Wang Z, Lin X, Gao F, Yang L, Shi D et al (2019) Trends of in-hospital mortality and constituent ratio of patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 47(3):209–214
18. Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS (2017) Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgrad Med 129(8):81–821
19. Noman A, Balasubramaniam K, Alhous MHA, Lee K, Jesudason P, Rashid M et al (2017) Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. Catheter Cardiovasc Intervent Off J Soc Cardiac Angiogr Interv 89(7):1195–1204
20. Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim Y-H, Feit F et al (2009) Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) substudy. JACC Cardiovasc Interv 2(8):748–757
21. Wang H-T, Chen Y-L, Wu C-J (2016) Impact of chronic kidney disease on clinical outcomes in patients with non-ST-elevation myocardial infarction receiving percutaneous coronary intervention—a five-year observational study. Int J Cardiol 220:166–172
22. Zhang M, Cheng Y-J, Zheng W-P, Liu G-H, Chen H-S, Ning Y, et al. Impact of chronic obstructive pulmonary disease on long-term outcome in patients with coronary artery disease undergoing percutaneous coronary intervention. BioMed Res Int. 2016;2016
23. Agarwal M, Agrawal S, Garg L, Garg A, Bhatia N, Kadaria D et al (2017) Effect of chronic obstructive pulmonary disease on in-hospital mortality and clinical outcomes after ST-segment elevation myocardial infarction. Am J Cardiol 119(10):1555–1559
24. Enriquez JR, de Lemos JA, Parkhiv SK, Peng SA, Sprott JA, Holper EM et al (2013) Association of chronic lung disease with treatments and outcomes in patients with acute myocardial infarction. Am Heart J 165(1):43–49
25. Wang Y, Zhu S, Du R, Zhou J, Chen Y, Zhang Q (2018) Impact of gender on short-term and long-term all-cause mortality in patients with non-ST-segment elevation acute coronary syndromes: a meta-analysis. Intern Emerg Med 13(2):273–285
26. McNamara RL, Kennedy KF, Cohen DJ, Diercks DB, Moscucci M, Ramee S et al (2016) Predicting in-hospital mortality in patients with acute myocardial infarction. J Am Coll Cardiol 68(6):626–635
27. Liang H, Guo YC, Chen LM, Li M, Han WZ, Zhang X et al (2016) Relationship between fasting glucose levels and in-hospital mortality in Chinese
patients with acute myocardial infarction and diabetes mellitus: a retrospective cohort study. BMC Cardiovasc Disord 16(1):156
28. Chehab O, Qannus A5, Eldirani M, Hassan H, Tamim H, Dakik HA (2018) Predictors of in-hospital mortality in patients admitted with acute myocardial infarction in a developing country. Cardiol Res 9(5):293–299
29. Emet S, Eltok A, Karaayvaz EB, Ergin B, Cevik E, Tuncozgur A et al (2019) Predictors of left ventricle ejection fraction and early in-hospital mortality in patients with ST-segment elevation myocardial infarction: Single-center data from a tertiary referral university hospital in Istanbul. SAGE Open Med 7:2050312119871785
30. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G (1997) Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96(12):4239–4245
31. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A (2001) Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker–based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 24(12):2091–2096
32. Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensin-converting–enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332(2):80–85

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.